Mood Disorders  >>  lorazepam extended-release (EDG004)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lorazepam extended-release (EDG004) / Edgemont Pharma
NCT02305797: EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)

Completed
3
495
US
Extended-release lorazepam, EDG004, Placebo
Edgemont Pharmaceuticals, LLC
Generalized Anxiety Disorder (GAD)
05/16
05/16

Download Options